News and press releases covering LASEROPTEK devices and technology are available in this corner.

Keep up to date with our global presence in the medical and aesthetics here.

  • LASEROPTEK Co., Ltd. Received CE Approval for HELIOS IV 785™

    The HELIOS IV 785™, a medical and aesthetic laser system, merges Pico and Nano wavelengths for absolute treatment outcomes and expanded indications. SEOUL, South Korea, June 3, 2021 / LASEROPTEK CO. LTD. / -- The HELIOS IV 785™, the world’s first high-powered Q-switched Nd:YAG laser with a 785nm picosecond pulse setting, has recently received CE mark. The unprecedented high-powered laser system’s unique and superior solid-state laser resonator – developed by LASEROPTEK – allows for both emission of dual 1064nm and 532nm nanosecond pulses and 785nm picosecond pulses all under a single platform. The HELIOS IV’s 785nm, like the 694nm, 730nm, and 755nm wavelengths, demonstrates strong melanin absorption curves for the effective treatment of pigmented lesions with minimal side effects. It has also been determined that the 785nm resembles closely the 1064nm counterpart, allowing for deeper penetration depths. The 785nm’s picosecond pulses alone may prove effective in the photomechanical breakdown of both natural and artificial pigmentations, but it may also be optimized for expanded indications in combination with 1064nm and 532nm nanosecond wavelengths. Designed to treat tattoo removal, benign pigmented lesions removal, acne scars, skin rejuvenation, and other skin-based indications, the HELIOS Series has sold more than 5,000 units in over 50 countries since its first release in 2003. Commanding a high market share across various global regions, including in Asia, market leaders and practitioners, who many still use the first model to date, praise the HELIOS Series for its high stability and performance during treatments. Expressing confidence in the HELIOS IV 785’s success across global markets, CJ Lee, CEO and President of LASEROPTEK, said: “Its development similarly resembles LASEROPTEK’s own history. “Just as the company is transitioning from stable management to an aggressive one, the HELIOS Series is also innovating. And after 18 years of demonstrating proven stability, the HELIOS Series now will introduce its very own 785nm picosecond laser that practitioners can use to optimize their existing treatment programs.” About LASEROPTEK Co., Ltd. LASEROPTEK is a global, technology-driven medical device company with a focus on aesthetic and medical lasers. Founded in 2000 and with in-house R&D capabilities, LASEROPTEK develops, manufactures, and markets safe, stable, and high-quality laser systems merging advanced laser technology with clinical efficacy. Media Contacts Helena Lee, Marketing Director jylee@laseroptek.com +82 2-2135-1990 Kyung Lee, Marketing Manager kyung@laseroptek.com +82 2-3474-1892 Visit us on social media: Facebook Instagram LinkedIn smart.bio/laseroptekco

    VIEW MORE +
  • LASEROPTEK Co., Ltd. Receives FDA 510(k) With Expanded Aesthetic Indications for its PicoLO™ Picosecond Nd:YAG Laser

    Nd:YAG True Picosecond Pulse Laser With Expanded Indications for Treatment of Benign Pigmented Lesions, Acne Scars, and Wrinkles SEOUL, Republic of Korea, April 23, 2021 / LASEROPTEK CO. LTD. / --  LASEROPTEK Co., Ltd., a developer and manufacturer of world-class laser devices for aesthetic and medical dermatology applications, is pleased to announce it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) expanding the indications for its PicoLO™ picosecond pulse Nd:YAG laser to include treatment of benign pigmented lesions, acne scars, and wrinkles. This 510(k) clearance represents a significant milestone in PicoLO’s evolution as a world-class picosecond pulse Nd:YAG laser delivering powerful and consistent photoacoustic generated Laser Induced Optical Breakdown (LIOB) within the skin to quickly and effectively fracture and finely fragment artificial and natural pigments such as in tattoos and benign pigmented lesions. PicoLO’s unique handpiece technology coupled with industry-leading energy and pulse duration stability provides clinicians the capability to selectively deliver LIOB to the dermis, upper dermis, and epidermis as desired. This LIOB depth control enables targeted micro wounding; catalyzing the body’s wound healing response consequently facilitating neocollagenesis and neoelastinogenesis that safely and effectively reduces the appearance of scars and wrinkles. LASEROPTEK’s President and CEO, CJ Lee, stated “The newly FDA-cleared indications for benign pigmented lesions, acne scars and wrinkles, added to PicoLO’s current indication for tattoo removal, marks PicoLO’s substantial progress in creating new opportunities for U.S. clinicians to deliver a wide range of safe, comfortable, and efficacious cosmetic laser procedures. This represents a further testament to our commitment to advance the development of laser-based energy devices bringing value to dermatologists, plastic surgeons, medical aesthetic practitioners, and their patients on a global basis,” added Mr. Lee. Dr. William Philip Werschler, MD, FAAD, commented “PicoLO’s new 510(k) with expanded cosmetic indications opens the door for cost-effective, advanced picosecond pulse laser skin rejuvenation treatments. We are excited to work with LASEROPTEK to offer PicoLO procedures to our patients at Spokane Dermatology and Werschler Aesthetics.” To learn more about PicoLO and the entire suite of LASEROPTEK aesthetic and medical dermatology laser systems, please contact Jayson Jonsson of Gale Force Aesthetics, LLC at +1(925) 705-6206 or visit www.laseroptek.com. About LASEROPTEK Co., Ltd. LASEROPTEK is a global, technology-driven medical device company with a focus on aesthetic and medical lasers. Founded in 2000 and with in-house R&D capabilities, LASEROPTEK develops, manufactures, and markets safe, stable, and high-quality laser systems merging advanced laser technology with clinical efficacy. Media Contacts Helena Lee, Marketing Director jylee@laseroptek.com +82 2-2135-1990 Christopher Dalton, Vice President dalton.christopher@laseroptek.com +1(619) 609-4757 Read the Press Release here: https://rebrand.ly/zj2bz55FDA510k

    VIEW MORE +
  • LASEROPTEK Receives PMDA Approval for PALLAS™

    SEOUL, Republic of Korea – January 6, 2021 – LASEROPTEK Co., Ltd. has announced PMDA approval for its PALLAS™ laser system. The PMDA, or Pharmaceuticals and Medical Devices Agency, is a pharmaceutical regulatory authority in Japan renowned for its strict licensing procedures. With that, PALLAS is the first-ever Korean device to be approved by the PMDA for treating chronic skin conditions including vitiligo, psoriasis, and atopic dermatitis. Most recently, LASEROPTEK’s PicoLO, HELIOS III, and LOTUS III laser systems also obtained licensing from Australia’s own regulatory body for medicines, medical devices, and diagnostics, the Therapeutic Good Administration (TGA). PALLAS is the world’s first solid-state Nd:YAG laser system that integrates 308nm and 311nm wavelengths designed to treat such conditions both effectively and safely – without the use of anesthetics – for people of all ages. PALLAS also reduces the cost of maintenance for users while operating the device daily. Following PMDA approval of PALLAS, C.J. Lee, CEO of LASEROPTEK, said the company is confident it can accelerate entry into global medical and aesthetic markets with cutting-edge laser systems supported by strong roots in R&D, and firm establishment of the company’s global network infrastructure. The clinical efficacies of PALLAS are featured in the Journal of American Medical Association (JAMA) Dermatology, Journal of the American Academy of Dermatology (JAAD), Wiley’s Photodermatology, Photoimmunology & Photomedicine, among other prestigious publications. About LASEROPTEK Co., Ltd. LASEROTPEK is a global developer and manufacturer of aesthetic and medical laser systems. Founded in 2000 with in-house R&D capabilities, LASEROPTEK offers safe, stable, and high-quality laser systems merging together advanced laser technologies with clinical efficacy. To learn more about PALLAS and the entire lineup of LASEROPTEK lasers, please visit us at www.laseroptek.com or email us at marketing@laseroptek.com.

    2021.01.14

  • LASEROPTEK Receives CE Mark for PicoLO Premium™, Opening the Door to the EU Market

    SEOUL, Republic of Korea - February 19, 2021 - A global developer and manufacturer of aesthetic and medical laser systems, LASEROPTEK Co., Ltd. is pleased to announce European CE Marking for its latest Picosecond Nd: YAG laser, PicoLO Premium™. Representing a significant upgrade from PicoLO which launched in 2018, PicoLO Premium takes efficacy and user convenience to the next level via a powerful lineup of next-generation handpieces. Handpieces include both a 1064nm and a 532nm Diffractive Optical Element (DOE) based fractional handpieces, a Collimator handpiece, a Zoom handpiece, and an exclusive S20 handpiece with a wider spot size for fast and efficient treatments. Boasting powerful and stable beam profiles, PicoLO Premium’s DOE fractional handpieces are also upgraded with a new look and branding. The “Dia FX®” 1064nm  ‘S’ handpiece enables highly delicate and defined area treatments with a new level of precision and efficacy. It also features a new and simple twist-and-treat function that allows users to quickly and easily select from three distinct laser energy penetration depths. Efficacious picosecond pulses targeting the deep dermis, upper dermis, and epidermis can now be accurately and repeatedly delivered helping clinicians create amazing outcomes. Additionally, the Dia FX 1064 handpiece also features two spot sizes for treating indications that require precision and customization. Commenting on PicoLO Premium’s CE Mark and incorporation into the company’s extensive line-up of cutting-edge laser systems, C.J. Lee, CEO of LASEROPTEK  said “PicoLO Premium’s CE Mark allows us to export a world-class laser that meets the exceptional standards and demands of European clinicians in their  respective regions.” “The company is well-equipped to face the rapidly changing medical and aesthetic market head-on as a pioneer in Europe and other global regions,” added Mr. Lee. Evidencing PicoLO Premium’s treatment efficacy for various indications, a recent study published in the Journal of European Academy of Dermatology and  Venereology concluded that the PicoLO Premium with the Dia FX 1064nm handpiece was proven to be more effective in treating acne scars with noticeable clinical improvements to skin pores and texture when compared to the non-ablative 1550nm Er: Glass laser. About LASEROPTEK Co., Ltd. LASEROTPEK is a global developer and manufacturer of aesthetic and medical laser systems. Founded in 2000 with in-house R&D capabilities, LASEROPTEK offers safe, stable, and high-quality laser systems merging together advanced laser technologies with clinical efficacy. To learn more about the new PicoLO Premium and the entire lineup of LASEROPTEK lasers, please visit us at www.laseroptek.com or email us at marketing@laseroptek.com. Media Contacts  Helena Lee, Marketing Director jylee@laseroptek.com +82 2-2135-1990 Kyung Lee, Marketing Manager kyung@laseroptek.com +82 2-3474-1892 Read the Press Release here: https://rebrand.ly/c2vuhu3PIPce  

    2021.02.19

  • Founder of LASEROPTEK HONG-CHU won the 2020 Industrial Technology Award of the Month with PicoLO laser

    Founder of LASEROPTEK HONG-CHU won the 2020 Industrial Technology Award of the Month with PicoLO laser. Awarded in the commercialization technology category for the development of a diagnosis/treatment system based on a wavelength tunable ultra-fast switching laser. Please pay more attention to PicoLO laser, which has succeeded in commercialization model with stabilized technology.

    2020.11.18